The Alpha 1A Adrenergic Receptor pipeline drugs market research report outlays comprehensive information on the Alpha 1A Adrenergic Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Alpha 1A Adrenergic Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Genito Urinary System, Central Nervous System, and Cardiovascular which include the indications Benign Prostatic Hyperplasia, Unspecified Genito Urinary Disorders, Alzheimer’s Disease, Dementia, Orthostatic Hypotension, and Idiopathic (Essential) Hypertension. It also reviews key players involved in Alpha 1A Adrenergic Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Alpha 1A Adrenergic Receptor pipeline targets constitutes close to 11 molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, and Preclinical stages are 1, 1, 1, 1, 3, 1, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Alpha 1A Adrenergic Receptor overview
Alpha-1A adrenergic receptor (ADRA1A) is a subtype of the alpha-1 adrenergic receptors, which are a class of G protein-coupled receptors. Alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G11 proteins.
For a complete picture of Alpha 1A Adrenergic Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
